Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Update

Posted by on Sep 15th, 2026

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD – Get Free Report) was the target of a significant drop in short interest during the month of August. As of August 31st, there was short interest totaling 19,643 shares, a drop of 47.3% from the August 15th total of 37,252 shares. Currently, 2.3% of the company’s shares are sold short. Based on an average trading volume of 55,975 shares, the short-interest ratio is presently 0.4 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company currently has an average rating of “Sell”.

Check Out Our Latest Research Report on Galmed Pharmaceuticals

Galmed Pharmaceuticals Stock Down 0.9%

GLMD stock traded down $0.04 during midday trading on Tuesday, reaching $4.59. The company’s stock had a trading volume of 302,067 shares, compared to its average volume of 52,894. The business’s 50-day simple moving average is $4.36 and its 200-day simple moving average is $4.71. Galmed Pharmaceuticals has a 52 week low of $3.29 and a 52 week high of $13.20. The stock has a market cap of $4.78 million, a PE ratio of -0.30 and a beta of 0.67.

Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last issued its earnings results on Wednesday, September 2nd. The biopharmaceutical company reported ($2.86) EPS for the quarter, beating the consensus estimate of ($3.12) by $0.26.

Galmed Pharmaceuticals Company Profile

(Get Free Report)

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.

Featured Stories

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.